Global Anticoagulants Market to Grow at a CAGR of 8.2% During 2024-2032, Aided by Increasing Incidence of Cardiovascular diseases

The primary driver for market expansion is the rising incidence and mortality rates of cardiovascular illnesses. The growing lifestyle concerns such as diabetes and obesity, as well as public health awareness, are driving the demand for more effective therapies. North America has the largest market share attributing to the rising mortality rates due to CVDs. Europe follows closely with over 11 million new cases of CVD being diagnosed every year, as per the European Society of Cardiology (ESC). The anticoagulant use has increased dramatically since the advent of NOACs. Its manufacturing and efficiency are increasing as pharmaceutical and therapeutic industries continue to grow and invest more in research and developments. The risks due to COVID-19 have prompted more investments in this sector. The increasing healthcare funding from the government and key market players is a major driver of market expansion.

In May 2019, Fragmin (dalteparin sodium) injection, for subcutaneous use, was approved by the US Food and Drug Administration (FDA) to decrease the recurrence of symptomatic venous thromboembolism (VTE) and mortality in paediatric patients aged one month and above. This has opened the industry to a different target market and further contributing to the market growth. As of January 2021, WHO recommended using low-dose anticoagulants in hospitalised patients to prevent blood clots from developing in blood arteries (thrombosis). According to NIH, full dose anticoagulation medications given to moderately unwell individuals hospitalised for COVID-19 reduced the need for critical organ support, such as breathing, in a large clinical trial done internationally in January 2021. A possible reduction in mortality was also noticed and is being investigated further. With the pandemic still in force, the need for anticoagulants in the healthcare industry is expected to increase over the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Drug Class, Application, and Region:

• The market, on the basis of drug class, can be divided into novel oral anticoagulants (NOACs), and heparin and low molecular weight heparin (LMWH), and vitamin K antagonist.

• Based on application, the industry can be divided into atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis (DVT), and pulmonary embolism, among others.

• The regional markets for anticoagulants market include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The primary driver for market expansion is the rising incidence and mortality rates of cardiovascular illnesses.

• The growing lifestyle concerns such as diabetes and obesity, as well as public health awareness, are driving the demand for more effective therapies.

• The use and expenditure of anticoagulant have dramatically increased since the advent of NOACs. The manufacturing and efficiency of the product are enhancing due to the thriving pharmaceutical industry.

• The higher incidence rate of COVID-19 has prompted more investment in the anticoagulant sector. The doses of anticoagulants reduced the need for critical organ support as well as mortality.

• The increasing healthcare funding from the government and key market players is a major driver for market expansion.

Key Offerings of the Report:

• The EMR report gives an overview of the global anticoagulants market for the periods (2018-2023) and (2024-2032).

• The report also offers the historical (2018-2023) and forecast (2024-2032) markets for the drug class, application, and regions of anticoagulants.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global market for anticoagulants are Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Aspen Pharmacare Holdings Limited, Pfizer Inc., and Portola Pharmaceuticals, Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790